AU2016264220A1 - Heterocyclic compounds as kinase inhibitors - Google Patents

Heterocyclic compounds as kinase inhibitors Download PDF

Info

Publication number
AU2016264220A1
AU2016264220A1 AU2016264220A AU2016264220A AU2016264220A1 AU 2016264220 A1 AU2016264220 A1 AU 2016264220A1 AU 2016264220 A AU2016264220 A AU 2016264220A AU 2016264220 A AU2016264220 A AU 2016264220A AU 2016264220 A1 AU2016264220 A1 AU 2016264220A1
Authority
AU
Australia
Prior art keywords
alkyl
cycloalkyl
cancer
compound
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016264220A
Other languages
English (en)
Inventor
Stephen Gately
Tong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Drug Development LLC
Original Assignee
TRANSLATIONAL DRUG DEV LLC
Translational Drug Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRANSLATIONAL DRUG DEV LLC, Translational Drug Development LLC filed Critical TRANSLATIONAL DRUG DEV LLC
Publication of AU2016264220A1 publication Critical patent/AU2016264220A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2016264220A 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors Abandoned AU2016264220A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562163369P 2015-05-18 2015-05-18
US62/163,369 2015-05-18
US201562203070P 2015-08-10 2015-08-10
US62/203,070 2015-08-10
PCT/US2016/033111 WO2016187324A1 (en) 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2016264220A1 true AU2016264220A1 (en) 2018-01-04

Family

ID=57320732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016264220A Abandoned AU2016264220A1 (en) 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors

Country Status (9)

Country Link
US (3) US10392402B2 (cg-RX-API-DMAC7.html)
EP (1) EP3297437A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018515623A (cg-RX-API-DMAC7.html)
CN (1) CN107835637A (cg-RX-API-DMAC7.html)
AU (1) AU2016264220A1 (cg-RX-API-DMAC7.html)
CA (1) CA3024113A1 (cg-RX-API-DMAC7.html)
HK (1) HK1248070A1 (cg-RX-API-DMAC7.html)
IL (1) IL255750A (cg-RX-API-DMAC7.html)
WO (1) WO2016187324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
PE20170143A1 (es) 2014-02-11 2017-03-19 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
CN105980365B (zh) 2014-02-11 2019-06-21 拜耳医药股份公司 作为mIDH1抑制剂的苯并咪唑-2-胺
AU2016264220A1 (en) * 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
WO2018094362A1 (en) 2016-11-21 2018-05-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors
JP7490569B2 (ja) * 2018-04-24 2024-05-27 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物、組成物および処置方法
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
CN114728926A (zh) * 2019-11-15 2022-07-08 武汉朗来科技发展有限公司 一种rock抑制剂及其制备方法和用途
CN113121443B (zh) 2019-12-31 2024-07-09 财团法人工业技术研究院 β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途
AU2021206651B2 (en) * 2020-01-07 2024-02-22 Disarm Therapeutics, Inc. Inhibitors of SARM1
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2022060812A1 (en) 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
KR20240176853A (ko) * 2023-06-15 2024-12-26 현대자동차주식회사 이중 전원 공급 장치, 그를 포함한 시스템 및 그 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
EP2234487A4 (en) 2007-12-19 2011-09-07 Scripps Research Inst ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE
US20090258907A1 (en) * 2008-04-09 2009-10-15 Abbott Laboratories Compounds useful as inhibitors of rock kinases
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
US9221808B2 (en) * 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9284298B2 (en) * 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
AU2016264220A1 (en) * 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors

Also Published As

Publication number Publication date
CA3024113A1 (en) 2016-11-24
US20200255448A1 (en) 2020-08-13
JP2018515623A (ja) 2018-06-14
US10633393B2 (en) 2020-04-28
IL255750A (en) 2018-01-31
WO2016187324A1 (en) 2016-11-24
US20180141959A1 (en) 2018-05-24
US10392402B2 (en) 2019-08-27
CN107835637A (zh) 2018-03-23
EP3297437A4 (en) 2019-02-27
HK1248070A1 (zh) 2018-10-12
US20200017520A1 (en) 2020-01-16
EP3297437A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
US10633393B2 (en) Heterocyclic compounds as kinase inhibitors
US10807966B2 (en) Heterocyclic compounds as kinase inhibitors
CA2441501C (en) Rho-kinase inhibitors
WO2002076976A2 (en) Rho-kinase inhibitors
CA2688326C (en) Tetrahydroisoquinolin-1-one derivative or salt thereof
KR20210150491A (ko) 포스파티딜이노시톨 3-키나제 저해제
CN102712601A (zh) 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
US20110212973A1 (en) Carbamate compound or salt thereof
US20230066011A1 (en) Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient
CA2863517A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
CA3078347A1 (en) Amide compounds as kinase inhibitors
CN103857658B (zh) 作为代谢型谷氨酸受体调节剂的乙炔基衍生物
WO2023051648A1 (zh) 可用作shp2抑制剂的化合物及其制备方法和用途
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
JP7490569B2 (ja) キナーゼ阻害剤としてのアミド化合物、組成物および処置方法
US11078161B2 (en) Rock-inhibiting compound and uses thereof
HK40013991A (en) Heterocyclic compounds as kinase inhibitors
HK40076191A (en) Imidazolidinone compound, preparation method therefor and use thereof
AU2021302681A1 (en) Novel compounds

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application